TNFSF11 and breast cancer: Current standard anti-resorptive drugs (bisphosphonates and the RANKL inhibitor, denosumab) inhibit bone resorption and reduce skeletal-related events (SREs)9,10, but they do not prolong patient survival, and 30-50% of BC patients on these drugs still develop new bone metastases9,11,12.